• Users Online: 232
  • Print this page
  • Email this page
Year : 2021  |  Volume : 64  |  Issue : 3  |  Page : 125-128

Effects of 100-km ultramarathon on erythropoietin variation in runners with hepatitis B virus carrier

1 Department of Pathology and Laboratory Medicine, Taipei Veterans General Hospital; PhD Program in Medical Biotechnology, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan
2 Department of Emergency Medicine, School of Medicine, College of Medicine, Taipei Medical University; Department of Emergency Medicine, Mackay Memorial Hospital, Taipei, Taiwan
3 Bavarian Center for Biomolecular Mass Spectrometry, Technische Universität München, Freising Deutschland, Germany
4 Department of Emergency Medicine, School of Medicine, College of Medicine, Taipei Medical University; Department of Emergency and Critical Care Medicine, Taipei Medical University Hospital, Taipei, Taiwan
5 Emergency Department, Taipei Veterans General Hospital; Department of Emergency Medicine, School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan

Correspondence Address:
Dr. Chorng-Kuang How
No. 201, Sec. 2, Shih-Pai Rd., Taipei 112
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/cjp.cjp_106_20

Rights and Permissions

Completing an ultramarathon leads to an immediate postrace surge of erythropoietin (EPO). Patients with chronic liver disease may have high plasma EPO concentrations. This study aims to explore whether plasma EPO concentrations vary between hepatitis B virus carrier (HBVc) and non-HBVc runners during long distance running. Blood samples were collected from 8 HBVc and 18 non-HBVc runners at 3 different time points: 1 week before, immediately following, and then 24 h after the 100-km ultramarathon race. Samples were analyzed for plasma EPO levels. EPO concentration had a statistically significant rise immediately after the race (8.7 [7.1–11.9] mU·mL−1 to 23.7 [14.8–37.2] mU·mL−1, P < 0.001) and maintained the high levels 24 h after the race finished (16.7 [11.5–21.0] mU·mL−1, P < 0.001) in all participants. The mean of EPO concentration was 8.9 (5.7–13.2) mU·mL−1 in HBVc runners and was 8.7 (7.7–11.2) mU·mL−1 in non-HBVc runners in the prerace. In HBVc runners, plasma EPO levels were no different at baseline (P = 0.657) and increased in the same fashion in response to ultramarathon compared with non-HBVc runners. Plasma EPO levels between the two groups were not statistically different at any time point. Prolonged endurance exercise led to a significant increase in EPO. A comparable increase in EPO levels was observed in HBVc and non-HBVc runners during and 24 h after 100-km ultramarathon. However, a small sample size might have affected the ability to detect a difference if it does exist.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded376    
    Comments [Add]    
    Cited by others 1    

Recommend this journal